1 minute read | January.22.2026
Think Bioscience raised $55 million in a Series A round, bringing its total capital raised to $78.25 million.
Orrick represented Think Bioscience.
Innovation Endeavors led the round, with participation from Janus Henderson and Regeneron Ventures.
Think Bioscience (Think Bio) is a privately held small molecule drug discovery company based in Boulder, Colorado. They are focused on developing therapeutics against targets that have historically been considered "undruggable". The company's team combines expertise in synthetic biology, protein biophysics, applied enzymology, computational chemistry, and medicinal chemistry to launch first-in-class program for diseases with high unmet need.
The funding will accelerate Think Bio's first-in-class initiatives, including its lead program targeting the genetic mutations that cause Noonan syndrome. This condition affects approximately 1 in 2,500 births and causes life-threatening cardiac and lymphatic complications, chronic pain, and cognitive impairment. No approved therapies currently address the disease's underlying biology.
"Our lead program has the potential to give a broad set of Noonan patients a better life," said Dr. Jerome Fox, co-founder and CEO at Think Bio. "We are grateful to our investors for supporting our vision to develop life-changing therapies."
Orrick’s Mark Solakian leads the team that advises Think Bio. The team also includes Jake Gatof, Reilly Clark and Jason Remy, with valuable support from Taylor Ball and Natalie Kerr.